PDF Version
TO: Pharmacies, Physicians, Physician Assistants, Nurse Practitioners,
Oral Surgeons, Optometrists, Dentists, FQHCs, RHCs, Mental Health Service
Providers and Nursing Homes
RE:
Preferred Drug List (PDL) and Pharmacy Quarterly
Update
Effective
January 1, 2026, the Alabama Medicaid Agency (Medicaid) will:
- Require
prior authorization (PA) for glycerol phenylbutyrate (generic Ravicti). Brand Ravicti will not require a PA and
will be billed with a Dispense as Written (DAW) Code of 9. DAW Code
of 9 indicates the following: Substitution Allowed by Prescriber but Plan
Requests Brand. This value is used when the prescriber has indicated, in a
manner specified by prevailing law, that generic substitution is
permitted, but the plan requests the brand product to be dispensed.
- Require prior authorization for clemastine syrup (generic
Tavist), conjugated estrogens tablets (generic Premarin tablets),
fluticasone/vilanterol (generic Breo Ellipta), and mirabegron (generic
Myrbetriq). Brand Breo Ellipta, Myrbetriq, and Premarin tablets will be
preferred and will be billed with a DAW Code of 9. DAW Code
of 9 indicates the following: Substitution Allowed by Prescriber but Plan
Requests Brand. This value is used when the prescriber has indicated, in a
manner specified by prevailing law, that generic substitution is
permitted, but the plan requests the brand product to be dispensed.
- Update
the PDL to reflect the quarterly updates listed below:
|
PDL Additions
|
|
alogliptin (generic
Nesina)
|
Dipeptidyl Peptidase-4
Inhibitors (DPP-4)
|
|
Ebglyss
CC
|
Skin
& Mucous Membrane Immunomodulatory
Agents
|
|
fluticasone/salmeterol (generic AirDuo Respiclick)
|
Respiratory
Corticosteroids
|
|
Mounjaro CC
|
Incretin Mimetics
|
|
Myrbetriq
|
Genitourinary Smooth Muscle Relaxants: Beta-3
Adrenergic Agonists
|
|
Nemluvio CC
|
Skin
& Mucous Membrane Immunomodulatory Agents
|
|
Premarin Cream
|
Estrogens
|
|
Rinvoq CC
|
TIMs/
DMARDs Agents
|
|
PDL
Deletions
|
|
Brilinta
|
Platelet-aggregation Inhibitors/ Vasodilating Agents,
Misc
|
|
Bydureon Bcise
|
Incretin Mimetics
|
|
clemastine syrup (generic
Tavist)
|
First-Generation Antihistamine Agents
|
|
conjugated estrogens tabs (generic Premarin tabs)
|
Estrogens
|
|
fluticasone/vilanterol (generic Breo Ellipta)
|
Respiratory Corticosteroids
|
|
mirabegron (generic
Myrbetriq)
|
Genitourinary Smooth Muscle Relaxants:
Beta-3Adrenergic Agonists
|
|
Nesina
|
Dipeptidyl Peptidase-4 Inhibitors (DPP-4)
|
|
Toviaz
|
Genitourinary Smooth Muscle Relaxants:
Antimuscarinics
|
CC This agent will be
preferred with clinical criteria in place.
For additional PDL and
coverage information, visit our drug look-up site at
https://www.medicaid.alabamaservices.org/alportal/NDC%20Look%20Up/tabId/5/Default.aspx.
The Prior
Authorization Request Form (Form 369) and criteria booklet (Form 369/389 Instructions) should be
utilized by the prescriber or the dispensing pharmacy when requesting a PA. The
request form can be completed and submitted electronically at https://medicaid.alabama.gov/content/9.0_Resources/9.4_Forms_Library/9.4.13_Pharmacy_Forms.aspx.
Providers requesting PAs by
mail or fax should send requests to:
Acentra Health
Medicaid Pharmacy Administrative Services
P.O. Box 3570, Auburn, AL 36831
Fax: 1-800-748-0116
Phone: 1-800-748-0130
Incomplete
PA requests or those failing to meet Medicaid criteria will be denied. If the
prescriber believes medical justification should be considered, the prescriber
must document this on the form or submit a written letter of medical
justification along with the PA form to Acentra Health. Additional information
may be requested. Staff physicians will review this information.